The author shares Novo Nordisk's U.S. launch of the oral Wegovy pill as a catalyst and discloses a long position.
NVO — LONG The author holds Novo Nordisk shares and highlights the U.S. launch of the Wegovy Pill as the key catalyst. The pill is priced at $149/month versus roughly $1,000 for injectables, with about 17% weight loss, and wide pharmacy/telehealth availability, positioning Novo to gain market share from Eli Lilly.
Novo Nordisk (NVO) has seen a significant boost in its stock over the last few trading days (in 5 days 11%), primarily driven by the official U.S. launch of the Wegovy Pill.
This Reddit post, published January 06, 2026, features u/charon-the-boatman discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/charon-the-boatman · Tickers: NVO